Age at onset of MS, years
| | | |
<20
|
59
|
14.5
| |
20–28
|
110
|
27.0
| |
29–38
|
119
|
29.2
| |
39–49
|
87
|
21.4
| |
≥50
|
32
|
7.9
| |
Sex
| | | |
Male
|
119
|
29.2
| |
Female
|
288
|
70.8
| |
Incomplete recovery from first relapse
| | | |
No
|
346
|
85.0
| |
Yes
|
61
|
15.0
| |
Initial course of MS
| | | |
Remitting-relapsing
|
349
|
85.7
| |
Primary progressive
|
58
|
14.3
| |
CSF total protein level, mg/L
| | | |
0–500
|
312
|
76.7
| |
≥500
|
95
|
23.3
| |
CSF IgG index
| | | |
<0.60
|
219
|
53.8
| |
≥0.60
|
188
|
46.2
| |
CSF oligoclonal bands
| | | |
No
|
53
|
13.0
| |
Yes
|
354
|
87.0
| |
Leukocyte count
| | | |
Normal
|
151
|
37.1
| |
Increased (≥5 mm3)
|
256
|
62.9
| |
Barkhof’s criteria (initial MRI)
| | | |
Negative
|
48
|
11.8
| |
Positive
|
359
|
88.2
| |
Period of MS onset
| | | |
<01/01/98
|
60
|
14.7
| |
≥01/01/98
|
347
|
85.3
| |
Time from MS onset to: (years)
| | | |
Lumbar puncture
|
407
| |
4.3 ± 3.2
|
Last follow-up
|
407
| |
8.9 ± 3.8
|